Key result
Systemic anticoagulation for AF in ESRD shows conflicting observational outcomes and lacks RCT guidance.
Why the study?
Data regarding the benefits and risks of anticoagulants in ESRD patients with AF are conflicting, and randomized controlled trial data are lacking to guide clinical decision-making.
Does systemic anticoagulation reduce stroke or systemic thromboembolism without excessive bleeding in patients with end-stage renal disease and atrial fibrillation?
Does systemic anticoagulation reduce stroke or systemic thromboembolism without excessive bleeding in patients with end-stage renal disease and atrial fibrillation?
The decision to anticoagulate ESRD patients with AF remains controversial due to conflicting observational data on efficacy and a paradoxically high risk of bleeding, necessitating an individualized multidisciplinary approach.
Net benefit of anticoagulation in ESRD-AF remains uncertain; conflicting data leave open need for RCTs.
End-stage renal disease (ESRD) patients have a higher prevalence of diabetes mellitus, hypertension, congestive heart failure and advanced age, along with an increased incidence of non-valvular atrial fibrillation (AF), thereby increasing the risk for cerebrovascular accidents. Systemic anticoagulation is therefore recommended in patients with ESRD with AF to reduce the risk and complications from thromboembolism. Paradoxically, these patients are at an increased risk of bleeding due to great degree of platelet dysfunction and impaired interaction between platelet and endothelium. Currently, CHA2DS2-VASc and Hypertension, Abnormal liver/kidney function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol (HAS-BLED) are the recommended models for stroke risk stratification and bleeding risk assessment in patients with AF. There is conflicting data regarding benefits and risks of medications such as antiplatelet agents, warfarin and direct oral anticoagulants in ESRD patients with AF. Moreover, there is no randomized controlled trial data to guide the clinical decision making. Hence, a multi-disciplinary approach with annual re-evaluation of treatment goals and risk-benefit assessment has been recommended. In this article, we review the current recommendations with risks and benefits of anticoagulation in patients with ESRD with AF.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2020) conducted a review in End-Stage Renal Disease and Atrial Fibrillation. Systemic anticoagulation (antiplatelets, warfarin, DOACs) was evaluated. Current observational data regarding the efficacy and safety of systemic anticoagulation in patients with end-stage renal disease and atrial fibrillation are conflicting, with no randomized controlled trials available to guide clinical decisions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: